20/20 BioLabs Targets Medicare Reimbursement for OneTest™ as Q2 Revenue Surges
Event summary
- 20/20 BioLabs held an investor webinar on July 1, 2026, outlining its strategy for Medicare reimbursement of OneTest™ for Cancer under a new statutory pathway starting in 2028.
- The company expects Q2 2026 revenue to be at least 30% higher than the prior-year period, marking its highest quarterly MCED revenue to date.
- OneTest™ differentiates itself with protein tumor markers, serial biomarker tracking, and at-home capillary blood collection, contrasting with circulating tumor DNA-based approaches.
- Over 35,000 American firefighters are expected to be tested by year-end 2026, providing real-world data to support regulatory and reimbursement strategies.
The big picture
20/20 BioLabs is positioning itself at the forefront of the emerging multi-cancer early detection (MCED) market, leveraging new Medicare reimbursement pathways and real-world evidence. The company's focus on affordability, accessibility, and serial biomarker tracking aligns with broader trends in preventive healthcare and federal initiatives aimed at chronic disease prevention. Success will hinge on navigating regulatory hurdles and demonstrating clinical utility in large-scale screening populations.
What we're watching
- Regulatory Pathway
- Whether OneTest™ can secure FDA authorization and CMS clinical appropriateness determination by 2028 to qualify for Medicare reimbursement.
- Revenue Growth
- The pace at which Q2 revenue growth translates into sustained profitability amid high regulatory and commercialization costs.
- Competitive Positioning
- How OneTest™'s protein biomarker approach and serial testing strategy will differentiate it from circulating tumor DNA-based MCED tests in the market.
Related topics